Reviewer's report

Title: Establishment of Hewga-clear cell sarcoma, a new clear cell sarcoma cell line, and investigation of the antitumor effects of pazopanib on Hewga-CCS: an in vitro and in vivo study

Version: 1 Date: 28 April 2014

Reviewer: Shan Naidu

Reviewer's report:

Overall it was a great study, with human metastatic clear cell sarcoma sample being used to create a stable cell line containing characteristic chromosomal alterations. The authors did an outstanding work in characterizing the cell line and targeting the activated c-MET pathway by Pazopanib, a novel tyrosine kinase inhibitor.

Discretionary Revisions

1) Although the authors addressed Pazopanib's effect on CCS xenografts against c-MET using western blot, it would be more convincing to have immunohistochemical analysis done for HGF/c-MET and VEGF after the treatment.

2) Although the original human CCS samples (supplementary figure 1) showed strong positivity for S-100, the xenografts were predominantly negative. It would be useful if the authors give a possible reason for the loss of S-100 immunoreactivity in xenografts in discussion section.

3) A minor suggestion: Rephrasing the sentence in lines 279-281 is suggested for the readers benefit.

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I declare that I have no competing interests